icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Boston MA
November 2019
Back grey_arrow_rt.gif
Outcomes of Patients Interrupting Glecaprevir/Pibrentasvir Treatment: A Case Series From Clinical Trials
  AASLD 2019 Nov 8-12 Boston
Reported by Jules Levin
Philippe Zamor1, John Dillon2, Douglas Dylla3, David Mutimer4, Reem Ghalib5, Massimo Colombo6, Richard Skoien7, Eric Crown3, Yiran Hu3, Eric Lawitz81Division of Hepatology, Carolinas Healthcare Systems, Charlotte, North Carolina, United States; 2Division of Molecular and Clinical Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom; 3AbbVie Inc., North Chicago, Illinois, United States; 4NIHR Liver Biomedical Research Unit, University of Birmingham, Birmingham, United Kingdom; 5Texas Clinical Research Institute, Arlington, Texas, United States; 6Center for Translational Hepatology Research, Clinical and Research Center Humanitas Hospital, Rozzano, Italy; 7Hepatic Fibrosis Laboratory, QIMR Berghofer Medical Research Institute, Queensland, Australia; School of Medicine, University of Queensland, Queensland, Australia; Department of Gastroenterology and Hepatology, Royal Brisbane and Women's Hospital, Queensland, Australia; 8The Texas Liver Institute, University of Texas Health San Antonio, San Antonio, Texas, United States